检索结果 - Zeming Mo

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)

    Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS) 由 Yiwen Bao, Jiaju Chen, Luting Duan, Fujue Wang, Han Lai, Zeming Mo, Weiliang Zhu

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  2. 2
    Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors

    Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors 由 Binglan Zhang, Diyuan Qin, Zeming Mo, Yi Li, Wei Wei, Yongsheng Wang, Wei Wang, Yuquan Wei

    出版 2016
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis

    A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis 由 Qizhi Ma, Xia He, Benxia Zhang, Fuchun Guo, Xuejin Ou, Qiyu Yang, Pei Shu, Yue Chen, Kai Li, Ge Gao, Yajuan Zhu, Diyuan Qin, Jie Tang, Xiaoyu Li, Jing Meng, Jian Zhao, Zeming Mo, Ning Liu, Yao Zeng, Kexun Zhou, Mingyang Feng, Wei‐Ting Liao, Wanting Lei, Qiu Li, Dan Li, Yongsheng Wang

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: